| Sep 30 |
J&J submits supplemental BLA for Darzalex Faspro to FDA
|
| Sep 30 |
J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program
|
| Sep 30 |
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
|
| Sep 30 |
J&J clinches EC approval for first single-pill PAH combo
|
| Sep 30 |
80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024
|
| Sep 30 |
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
|
| Sep 30 |
Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial
|
| Sep 30 |
15 Best Dividend Stocks for Lifelong Passive Income
|
| Sep 30 |
Johnson & Johnson (JNJ): Hedge Funds Bet Big on Healthcare Giant Amid 4.3% Q2 Revenue Increase
|
| Sep 28 |
Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study
|
